Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | KDM5A | P29375 | 4/20 | 0.40 |
| ▸ | PHF8 | Q9UPP1 | 4/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.40 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | LSS | P48449 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5179125 | 0.87 | — | — | |
| SCHEMBL10570592 | 0.84 | CYP1A2 (0.52) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL6753110 | 0.84 | CYP1A2 (0.59) | SIGMAR1CYP1A2HTTLMNAMAPK1 | |
| SCHEMBL330316 | 0.84 | SIGMAR1 (0.42) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL129838 | 0.84 | — | — | |
| SCHEMBL2048536 | 0.84 | — | — | |
| SCHEMBL3390757 | 0.84 | SIGMAR1 (0.42) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL1534917 | 0.84 | SIGMAR1 (0.42) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL6749100 | 0.84 | CYP1A2 (0.59) | SIGMAR1CYP1A2HTTLMNAMAPK1 | |
| SCHEMBL131734 | 0.84 | SIGMAR1 (0.42) | SIGMAR1CYP1A2KDM5APHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142178-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140121267-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2014-05-01 | — | — | US | disclosed |
| US-8623897-B2 | Methods and compositions for treatment of diabetes and dyslipidemia | KAREUS THERAPEUTICS, SA (CH) | 2014-01-07 | — | — | US | disclosed |
| US-20120071528-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071528-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | LIPC, PNLIP, LIPA | SIGMAR1 3578/4885CYP1A2 655/4885KDM5A 2708/4885 |
| US-20140121267-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | GPR119, FFAR1, INSR | SIGMAR1 204/4885CYP1A2 699/4885KDM5A 3800/4885 |
| US-20140142178-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | DHCR7, INSR, GPR119 | SIGMAR1 307/4885CYP1A2 659/4885KDM5A 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.